Welcome to our dedicated page for Teladoc Health news (Ticker: TDOC), a resource for investors and traders seeking the latest updates and insights on Teladoc Health stock.
Teladoc Health reports news on its virtual care business, including financial results, segment performance, product innovation, technology investment, and governance updates. The company delivers and orchestrates care across patients, care providers, platforms, and partners through relationships with health plans, employers, providers, health systems, and consumers.
Recurring updates focus on Integrated Care, which includes virtual care solutions such as primary care, mental health, chronic care management, and telehealth enablement, and BetterHelp, the company’s direct-to-consumer online mental health offering. Company news also includes earnings calls, investor conference participation, board appointments and retirements, inducement equity awards, and strategic commentary on its clinical model and care-delivery platform.
Teladoc Health (NYSE:TDOC) announced an employment inducement award effective March 1, 2026, for Daniel Conroy as Chief Growth Officer, U.S. Group Health. The grant includes 57,034 restricted stock units and 57,034 performance stock units (target), with up to 114,068 PSU shares earnable.
RSUs vest one-third at the first anniversary, then quarterly over two years; PSUs vest based on three-year financial metrics. The award was approved by the Compensation Committee under the 2023 Employment Inducement Incentive Award Plan per NYSE Rule 303A.08.
Teladoc Health (NYSE: TDOC) said CEO Chuck Divita will present at the Barclays 28th Annual Global Healthcare Conference in Miami on March 10, 2026 at 1:00 p.m. ET. A live audio webcast and replay will be available on the company investor site.
Teladoc Health (NYSE: TDOC) reported Fourth Quarter 2025 revenue of $642.3M (flat YoY) and full-year 2025 revenue of $2,530.0M (down 2% YoY). Q4 net loss was $25.1M and FY net loss was $200.3M.
Adjusted EBITDA was $83.8M in Q4 (up 12% YoY) and $281.1M for FY 2025 (down 10% YoY). Operating cash flow was $294.4M for FY 2025 and cash on hand was $781.1M. Company provided 2026 outlook ranges for revenue, adjusted EBITDA, and FCF.
Teladoc Health (NYSE: TDOC) appointed Michael Smith to its board of directors effective Feb 18, 2026, following the retirements of Eric Evans and Thomas McKinley. Mr. Smith will serve on the board’s audit and nominating and corporate governance committees and brings 30+ years of financial and transformation experience.
He is executive chairman of Talcott Financial Group with $130 billion assets under management and is a former CFO of Voya Financial. Teladoc will report fourth-quarter 2025 results on Feb 25, 2026 and host a conference call at 5:00 p.m. ET.
Teladoc Health (NYSE: TDOC) will release its fourth quarter 2025 results on Wednesday, February 25, 2026, after market close, and will host a conference call the same day at 5:00 p.m. ET. Investors can access the call by phone, global dial-in, or a live audio webcast.
A replay will be available via webcast shortly after the call and remain online for approximately 90 days.
Teladoc Health (NYSE: TDOC) on January 12, 2026 launched enhanced 24/7 Care nationwide, expanding its virtual urgent care capabilities. Enhancements enable care teams to treat a broader range of conditions (eg, back and joint pain, hair loss, sleep issues), support medication optimization for hypertension, diabetes, asthma and COPD, and access board-certified specialists via seconds‑long provider-to-provider consults.
The service now integrates claims and HIE data to prompt preventive actions (70% of members agreed to recommendations) and displays prescription benefits in real time; recent data show >95% of member concerns are resolved in a single visit. The update is powered by the Prism care delivery platform and connects patients to in-network care and Teladoc programs.
Teladoc Health (NYSE: TDOC) said CEO Chuck Divita will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 3:45 p.m. PT (6:45 p.m. ET). A live audio webcast and replay will be available on the company's investor relations site.
Investors can listen live or view the replay at the investor events page: https://ir.teladochealth.com/news-and-events/events-and-presentations.
Teladoc Health (NYSE: TDOC) announced that CEO Chuck Divita will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025 at 12:30 p.m. ET.
A live audio webcast and replay will be available via the company’s investor events page at http://ir.teladochealth.com/news-and-events/events-and-presentations/. Contact for investors is Michael Minchak at IR@teladochealth.com or 617-444-9612.
TytoCare will integrate its FDA-cleared home diagnostic technology with Teladoc Health (NYSE: TDOC) to augment Primary360 and 24/7 Care programs. The integration will begin in 2026 with a phased rollout to select customers and enables remote clinical-grade exams (lungs, throat, ear, heart, skin, temperature) using TytoCare's handheld device and AI-powered Lung Sounds Suite.
Key facts: FDA clearance for the AI Lung Sounds Suite; respiratory conditions represent >40% of TytoCare diagnoses; AI trained on >7 million exams.
Teladoc Health (NYSE:TDOC) announced an employment inducement award effective November 1, 2025 for new Chief Technology Officer Dave Ross. The grant includes 86,906 restricted stock units (RSUs) and 86,906 performance stock units (PSUs) at target (up to 173,812 shares if maximum is earned).
The RSUs vest with one-third on the first anniversary and the remainder quarterly over the next two years. The PSUs are earned over a three-year performance period based on specified financial metrics. The award was approved by the Compensation Committee and granted under the Teladoc Health 2023 Employment Inducement Incentive Award Plan as permitted by NYSE Rule 303A.08.